5-hydroxyuracil,
496-76-4,
1,3-diazinane-2,4,5-trione,
Dihydropyrimidine-2,4,5(3H)-trione,
2,4,5(3H)-Pyrimidinetrione, dihydro-,
UNII-438WJI1S49,
438WJI1S49,
NSC 95958,
IsobarbituricAcid,
AC1L3XMF,
AC1Q6DDR,
(1h,3h,5h)pyrimidinetrione,
SCHEMBL2491820,
FQXOOGHQVPKHPG-UHFFFAOYSA-N,
Isobarbituric acid (VAN) (8CI),
2,4,5-Trihydroxypyrimidine, 98%,
NSC95958,
ZINC1621573,
EINECS 207-829-9,
FCH949706,
MFCD00082987,
NSC-95958,
2,5(3H)-Pyrimidinetrione, dihydro-,
Dihydro-2,4,5(3H)-pyrimidinetrione,
AKOS006223247,
Isobarbituric acid, analytical standard,
ACM20636413,
KS-000015Q6,
Dihydro-2,4,5(3H)-pyrimidinetrione #,
636T413,
A827793,
Dihydropyrimidine-2,4,5(3H)-trione (Isobarbituric Acid; 5-Hydroxyuracil),
Fluorouracil impurity B, European Pharmacopoeia (EP) Reference Standard,
Fluorouracil Related Compound B, United States Pharmacopeia (USP) Reference Standard,
5-Hydroxyuracil,
Isobarbituric acid,
2,4,5-Trihydroxypyrimidine,
5-hydroxy uracil,
CID96994,
AR-1D2910,
CS-O-06003,
2,4,5(3H)-Pyrimidinetrione, dihydro- (9CI),
20636-41-3,
5180-76-7,